Log In


Reset Password
  • MENU
    Local
    Thursday, August 11, 2022

    Pfizer to spend $11.6B on migraine treatment maker Biohaven

    FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer is spending more than $11 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own. The New York drugmaker said Tuesday, May 10, 2022, it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development. (AP Photo/Mark Lennihan, File)

    Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. 

    The New York vaccine and cancer drug maker said Tuesday it will use cash on hand to buy the remaining portion of migraine treatment developer Biohaven Pharmaceutical it does not already own.

    Pfizer will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has a nasal spray under development.

    Pfizer Inc. brought in more than $14 billion in sales during the recently completed first quarter from its COVID-19 vaccine Comirnaty and its new pill treatment for the virus, Paxlovid.

    Most of that came from Comirnaty, which also rang up nearly $37 billion in sales last year. But revenue from Comirnaty, which Pifzer developed with BioNTech, is expected to fade in the coming years. Pfizer also faces the loss of patent protection for some key products in its broad portfolio over the next decade.

    That includes Eliquis for preventing blood clots and strokes and the Prevnar 13 vaccine for preventing pneumonia and related bacterial diseases.

    The company plans to have about $25 billion in sales by 2030 come from new business developments.

    The deal announced Tuesday is a step in that direction. Pfizer currently has no migraine treatments. U.S. regulators approved Nurtec ODT — which stands for orally disintegrating tablet — for treating migraines in February 2020 and for preventing them about a year ago.

    The drug is sold as Vydura in the European Union.

    It brought in nearly $124 million in sales in the first quarter. Biohaven expects $825 to $900 million in product sales this year.

    Pfizer plans to put its marketing muscle into the drug with potential launches for it in 70 countries.

    Last November, Pfizer said it would invest $350 million in Biohaven to help sell Nurtec ODT and the spray, zavegepant, outside the United States.

    Pfizer said Tuesday the spray is on track for U.S. acceptance in the current quarter, and an oral gel version of it also is being developed for preventing chronic migraines.

    Pfizer executives told analysts they expect annual revenue from Nurtec ODT and the spray to eventually peak above $6 billion.

    The pharmaceutical giant is an “ideal acquirer” of Biohaven's portfolio in part because of its strong presence in primary care, its cash position and its need for new growth drivers, Mizuho Securities USA analyst Dr. Vamil Divan said in a research note.

    The deal for Biohaven also includes some other potential treatments in early stages of development.

    Other elements of Biohaven’s late-stage development pipeline will go to a new, publicly traded company that keeps the Biohaven name.

    The boards of both Pfizer and Biohaven have approved the sale. Biohaven shareholders, who will receive a stake in the new company, and regulators still need to ok it.

    The deal is expected to close by early 2023.

    Shares of Biohaven Pharmaceutical Holding Company Ltd. which is based in New Haven, Connecticut, soared almost 70% to $141.20 in midday trading.

    Pfizer's stock climbed about 1% to $49.20 as broader trading indexes slipped.

    Post your comment

    We encourage respectful comments but reserve the right to delete anything that does not contribute to an engaging dialogue. Help us moderate this thread by flagging comments that violate our guidelines. Read the commenting policy.